Wednesday, July 8, 2026

pharma · Acne Vulgaris · Pruritus · VYNE

VYNE Therapeutics

Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa,

520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
Status
Public
HQ
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
Founded
2003
Employees
47
Programs
30
Drugs
16
Patents
7

Quick answer

Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa, Refractory Chronic Cough. NovaPharmaNews links 30 clinical program(s), 0 drug profile(s), and 7 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (19), phase 3 (6), phase 1 (4).

Company snapshot

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by

  • 30 active pipeline program(s) linked via ClinicalTrials.gov.
  • 7 US patent(s) indexed to this assignee profile.
  • 30 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for VYNE Therapeutics. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for VYNE Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 37 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for VYNE Therapeutics.

  1. Clinical update

    Topical Minocycline Foam FXFM244 — Phase 2

  2. Clinical update

    Topical Minocycline Foam FXFM244 — Phase 2

  3. Clinical update

    Topical Minocycline Foam FXFM244 — Phase 2

  4. Clinical update

    Isotretinoin — Approved

  5. Clinical update

    FDX104 (4% Doxycycline) — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is VYNE Therapeutics?

    Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa, Refractory Chronic Cough. NovaPharmaNews links 30 clinical

  • Is VYNE Therapeutics publicly traded?

    Yes. VYNE Therapeutics is listed with ticker VYNE on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does VYNE Therapeutics develop or market?

    We link 16 drug profile(s) where VYNE Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vyne-therapeutics#company-drugs.

  • What are the latest developments for VYNE Therapeutics?

    In the last 12 months our linked public records show 30 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does VYNE Therapeutics focus on?

    VYNE Therapeutics focuses on Acne Vulgaris, Pruritus, Rosacea based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
42
Cardiology
1